{"id":45940,"date":"2025-11-05T23:08:17","date_gmt":"2025-11-05T15:08:17","guid":{"rendered":"https:\/\/flcube.com\/?p=45940"},"modified":"2025-11-05T23:08:19","modified_gmt":"2025-11-05T15:08:19","slug":"ucb-wins-fda-approval-for-kygevvi-in-rare-mitochondrial-disease-tk2d","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45940","title":{"rendered":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d"},"content":{"rendered":"\n<p><strong>UCB (<a href=\"https:\/\/www.google.com\/finance\/quote\/UCB:EBR\">EBR: UCB<\/a>)<\/strong> announced that <strong>KYGEVVI<\/strong> received <strong>FDA approval<\/strong> for the treatment of <strong>adult and pediatric patients<\/strong> with <strong>thymidine kinase\u00a02 deficiency (TK2d)<\/strong>, with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-fda-announcement\">Key FDA Announcement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>KYGEVVI (UCB\u2019s novel therapy)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult &amp; pediatric patients with TK2d, symptom onset \u2264\u202f12\u202fyears<\/td><\/tr><tr><td><strong>Regulator<\/strong><\/td><td>U.S. Food &amp; Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First and only approved treatment for this ultra\u2011rare mitochondrial myopathy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-disease-thymidine-kinase-nbsp-2-deficiency-tk2d\">The Disease \u2013 Thymidine Kinase&nbsp;2 Deficiency (TK2d)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ultra\u2011Rare, Life\u2011Threatening Genetics<\/strong> \u2013 Progressive myopathy with no therapeutic options beyond supportive care until now.<\/li>\n\n\n\n<li><strong>Typical Course<\/strong> \u2013 Rapid decline; patients with early onset face a 3\u2011year chance of premature death after symptom appearance.<\/li>\n\n\n\n<li><strong>Population<\/strong> \u2013 Roughly 200 diagnosed worldwide, largely under 12\u202fyears of age.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-kygevvi\">Clinical Evidence Supporting KYGEVVI<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202f2 Study<\/strong> \u2013 Randomized, 78\u2011patient cohort, median symptom onset 1.5\u202fyears.<\/li>\n\n\n\n<li><strong>Retrospective Chart Reviews<\/strong> \u2013 2 studies reinforcing efficacy.<\/li>\n\n\n\n<li><strong>Expanded Access Program<\/strong> \u2013 Real\u2011world data included in survival analysis.<\/li>\n<\/ul>\n\n\n\n<p><strong>Efficacy Highlights<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Median Age of Symptom Onset<\/strong><\/td><td>1.5\u202fyears<\/td><\/tr><tr><td><strong>Median Treatment Duration<\/strong><\/td><td>4\u202fyears<\/td><\/tr><tr><td><strong>Median Dose<\/strong><\/td><td>762\u202fmg\/kg\/day<\/td><\/tr><tr><td><strong>Overall Risk of Death Reduction<\/strong><\/td><td>~\u202f86\u202f% (95\u202f%\u202fCI:\u202f61\u202f%\u202f\u2013\u202f96\u202f%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The data demonstrate a substantial survival benefit, reducing mortality risk by roughly 86% from treatment initiation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-and-regulatory-impact\">Market and Regulatory Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011In\u2011Class Approval<\/strong> \u2013 Positions UCB as a leader in mitochondrial disease therapeutics.<\/li>\n\n\n\n<li><strong>Pricing &amp; Reimbursement<\/strong> \u2013 Likely to prompt discussions on high\u2011cost, high\u2011value orphan drugs in the U.S. reimbursement space.<\/li>\n\n\n\n<li><strong>Patient Advocacy<\/strong> \u2013 Opens pathways for early diagnosis and intervention, improving patient and family outcomes.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h2>\n\n\n\n<p>UCB\u2019s <strong>KYGEVVI<\/strong> launch marks a watershed moment for <strong>TK2d<\/strong> patients, offering the only proven disease\u2011modifying therapy for adults and children with early onset. The FDA approval, underpinned by robust Phase\u20112 and real\u2011world data, delivers a critical lifeline to an ultra\u2011rare, lethal condition and sets a precedent for future mitochondrial disease treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2015,15,24,131],"class_list":["post-45940","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ebr-ucb","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-ucb"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45940\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d\" \/>\n<meta property=\"og:description\" content=\"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45940\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T15:08:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T15:08:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d\",\"datePublished\":\"2025-11-05T15:08:17+00:00\",\"dateModified\":\"2025-11-05T15:08:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0510.webp\",\"keywords\":[\"EBR: UCB\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"UCB\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45940#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45940\",\"name\":\"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0510.webp\",\"datePublished\":\"2025-11-05T15:08:17+00:00\",\"dateModified\":\"2025-11-05T15:08:19+00:00\",\"description\":\"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45940\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0510.webp\",\"width\":1080,\"height\":608,\"caption\":\"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45940#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d - Insight, China&#039;s Pharmaceutical Industry","description":"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45940","og_locale":"en_US","og_type":"article","og_title":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d","og_description":"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.","og_url":"https:\/\/flcube.com\/?p=45940","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T15:08:17+00:00","article_modified_time":"2025-11-05T15:08:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45940#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45940"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d","datePublished":"2025-11-05T15:08:17+00:00","dateModified":"2025-11-05T15:08:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45940"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45940#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","keywords":["EBR: UCB","Product approvals","Rare \/ orphan disease drugs","UCB"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45940#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45940","url":"https:\/\/flcube.com\/?p=45940","name":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45940#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45940#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","datePublished":"2025-11-05T15:08:17+00:00","dateModified":"2025-11-05T15:08:19+00:00","description":"UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and pediatric patients with thymidine kinase\u00a02 deficiency (TK2d), with symptom onset at or before age\u202f12. It is the single approved therapy for this ultra\u2011rare, life\u2011threatening mitochondrial disorder.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45940#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45940"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45940#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","width":1080,"height":608,"caption":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45940#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45940"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45940\/revisions"}],"predecessor-version":[{"id":45942,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45940\/revisions\/45942"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45941"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}